Small Cell Lung Carcinoma

• EMA withdrawal · 2026-08-25
  EMA Application withdrawn: Zinmyleo (trilaciclib dihydrochloride) — Pharmacosmos A/S

  The EMA has withdrawn the application for Zinmyleo (trilaciclib dihydrochloride) by Pharmacosmos A/S for small cell lung carcinoma.

• EMA withdrawal · 2019-03-07
  EMA Withdrawn: Topotecan Actavis (topotecan) — Actavis Group PTC ehf

  EMA withdrawn topotecan (Topotecan Actavis) indicated for uterine cervical neoplasms and small cell lung carcinoma; product withdrawn by MAH…

• EMA withdrawal · 2018-07-13
  EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.

  Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and …

• EMA withdrawal · 2014-11-14
  EMA Withdrawn: Topotecan Eagle (topotecan hydrochloride) — Eagle Laboratories Ltd.

  EMA has withdrawn Topotecan Eagle (topotecan hydrochloride) from the market.